Results 11 to 20 of about 8,310 (206)

Medication-related osteonecrosis of the jaw

Revista Brasileira de Odontologia, 2018
.
Heliton Spindola Antunes, Rogerio Jardim Caldas, Fabiana Caramori Noal Granzotto, Geisa Badauy Lauria da Silva, Walmir Mello, Paulo Sérgio da Silva Santos   +5 more
doaj   +3 more sources

Medication-related osteonecrosis of the jaw: Prosthodontic considerations

Japanese Dental Science Review, 2022
Medication-related osteonecrosis of the jaw (MRONJ) can be triggered by several antiresorptive and antiangiogenic medications, including bisphosphonates (BRONJ), denosumab (DRONJ), and other agents used to treat osteoporosis and metastatic bone cancer ...
Islam E. Ali, Yuka Sumita
doaj   +3 more sources

Medication-Related Osteonecrosis of the Jaw—A Continuing Issue [PDF]

Applied Sciences, 2021
Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a condition that is becoming more common in the everyday practice of both dental and maxillofacial surgeons.
Krzysztof Wróbel, Maciej Sikora, Maciej Chęciński, Maria Jas, Dariusz Chlubek   +4 more
doaj   +2 more sources

Medication-Related Osteonecrosis of the Jaw [PDF]

, 2017
Osteonecrosis of the jaw (ONJ) is a common side effect of antiresorptive drugs that are administered to cancer patients for bone metastasis, multiple myeloma, and osteoporosis.
Bukawa, Hiroki, Kanno, Naomi, Uchida, Fumihiko, Yamagata, Kenji, Yanagawa, Toru   +4 more
core   +5 more sources

Adalimumab: Another Medication Related to Osteonecrosis of the Jaws? [PDF]

Case Reports in Dentistry, 2016
Objective. The acronym MRONJ has been created in order to identify “Medication-Related Osteonecrosis of the Jaw,” observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in
Andrea Cassoni, Umberto Romeo, Valentina Terenzi, Marco Della Monaca, Oriana Rajabtork Zadeh, Ingrid Raponi, Maria Teresa Fadda, Antonella Polimeni, Valentino Valentini   +8 more
doaj   +4 more sources

Alterations of bone proteins in medication-related osteonecrosis of the jaw. [PDF]

Eur J Oral Sci
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Schubert A, Brockmeyer P, Kauffmann P, Wiegel J, Lautenbacher F, Miosge N, Schminke B.   +6 more
europepmc   +2 more sources

How we manage medication-related osteonecrosis of the jaw

European Journal of Medical Research
Bone-modifying agents (BMAs) are integral to managing patients with advanced cancer. They improve quality of survival by reducing skeletal-related events, treating hypercalcaemia and chemotherapy-induced bone loss (Coleman in Clin Cancer Res 12: 6243s ...
H. Byrne, S. O’Reilly, C. S. Weadick, P. Brady, R. Ni Ríordáin   +4 more
doaj   +4 more sources

Effect of metformin on inflammation and bone damage in a rat model of medication-related osteonecrosis of the jaw. [PDF]

Eur J Oral Sci
Abstract This study investigated how chronic metformin administration modulates the cellular profile and inflammatory markers in a zoledronic acid‐based rat model of medication‐related osteonecrosis of the jaw (MRONJ). Male Wistar rats were allocated to different treatments: (i) naïve, (ii) MRONJ (zoledronic acid, 0.2 mg/kg, i.v.
Rabelo LMA, Guimarães MV, Cajado AG, Lemos JVM, de Sousa FD, Alencar NMN, de Lima V, de Barros Silva PG, Alves APNN, Wong DVT, Lima-Júnior RCP.   +10 more
europepmc   +2 more sources

Medication-Related Osteonecrosis of the Jaws

JNCI Monographs, 2019
AbstractMedication-related osteonecrosis of the jaw is an oral complication in cancer patients being treated with either antiresorptive or antiangiogenic drugs. The first reports of MRONJ were published in 2003. Hundreds of manuscripts have been published in the medical and dental literature describing the complication, clinical and radiographic signs ...
Cesar A, Migliorati, Michael T, Brennan, Douglas E, Peterson   +2 more
openaire   +4 more sources

Medication-related Osteonecrosis of the Jaw: A Review [PDF]

Cureus, 2020
Medication-related osteonecrosis of the jaw (MRONJ) is a rare, severe debilitating condition from unknown causes. It is characterized by nonhealing exposed bone in a patient with a history of antiresorptive or antiangiogenic agents in the absence of radiation exposure to the head and neck region. The first case of MRONJ was reported in the early 2000s.
AlDhalaan, Nouf A, BaQais, Asma, Al-Omar, Ahmad   +2 more
openaire   +2 more sources